Paenidigyamycin g: 1-acetyl-2,4-dimethyl-3-phenethyl-1H-imidazol-3-ium

MakaleAçık ErişimScopus SJRQ4
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

The Ghanaian Paenibacillus sp. DE2SH (GenBank Accession Number: MH091697) is a prolific producer of potent antiparasitic alkaloids. Further detailed study of the culture broth of this strain produced the compound Paenidigyamycin G (1), which is a derivative of the known antiparasitic compound Paenidigyamycin A (2). Compound (1) was isolated on HPLC at tR ≈ 37.5 min and its structure determined by IR, UV, MS, 1D, and 2D-NMR data. Compound 1 produced weak to moderate antileishmanial and antitrypanosomal activity when tested against Leishmania donovani (Laveran and Mesnil) Ross (D10) and Trypanosoma brucei subsp. brucei strain GUTat 3.1 with IC50 = 115.41 and 28.75 µM, respectively. This result is interesting since the parent compound 2 is known to possess consistent and potent antiparasitic activity. However, 1 displayed a promising selectivity profile towards T. brucei subsp. brucei due to its relatively low toxicity against normal mouse macrophages RAW 264.7 cells (SI = 8.70). Given that compound 1 is also the main metabolite found in the hexane fraction of all extracts produced by Paenibacillus sp. DE2SH when it is co-cultured with other bacteria strains, it must possess some unique biological functions which should make it an excellent candidate for further biological activity screening in other bioassays.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/munzur/3559Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.3390/m1094Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
4
WoS
3
OpenAlex
4
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorTetevi, Gilbert Mawuli
dc.contributor.authorKwain, Samuel
dc.contributor.authorMensah, Thomas
dc.contributor.authorCamas, Anil Sazak
dc.contributor.authorCamas, Mustafa
dc.contributor.authorDofuor, Aboagye Kwarteng
dc.contributor.authorAzerigyik, Faustus Akankperiwen
dc.contributor.authorOluwabusola, Emmanuel
dc.contributor.authorDeng, Hai
dc.contributor.authorJaspars, Marcel
dc.contributor.authorKyeremeh, Kwaku
dc.date.accessioned2026-10-28T14:56:47.672573492Z
dc.date.available2026-10-28T14:56:47.672573492Z
dc.date.issued2019
dc.description.abstractThe Ghanaian Paenibacillus sp. DE2SH (GenBank Accession Number: MH091697) is a prolific producer of potent antiparasitic alkaloids. Further detailed study of the culture broth of this strain produced the compound Paenidigyamycin G (1), which is a derivative of the known antiparasitic compound Paenidigyamycin A (2). Compound (1) was isolated on HPLC at tR ≈ 37.5 min and its structure determined by IR, UV, MS, 1D, and 2D-NMR data. Compound 1 produced weak to moderate antileishmanial and antitrypanosomal activity when tested against Leishmania donovani (Laveran and Mesnil) Ross (D10) and Trypanosoma brucei subsp. brucei strain GUTat 3.1 with IC50 = 115.41 and 28.75 µM, respectively. This result is interesting since the parent compound 2 is known to possess consistent and potent antiparasitic activity. However, 1 displayed a promising selectivity profile towards T. brucei subsp. brucei due to its relatively low toxicity against normal mouse macrophages RAW 264.7 cells (SI = 8.70). Given that compound 1 is also the main metabolite found in the hexane fraction of all extracts produced by Paenibacillus sp. DE2SH when it is co-cultured with other bacteria strains, it must possess some unique biological functions which should make it an excellent candidate for further biological activity screening in other bioassays.
dc.description.sponsorshipCambridge-Africa Partnership for Research Excellence
dc.description.sponsorshipMauritius Research Council, MRC
dc.description.sponsorshipCarnegie
dc.description.sponsorshipMSD K.K.
dc.description.sponsorshipUniversity of Ghana, UG
dc.description.sponsorshipDepartment for International Development, UK Government, DFID
dc.description.sponsorshipDepartment for International Development, DFID
dc.description.sponsorshipCarnegie Corporation of New York, CCNY
dc.description.sponsorshipMRC/DFID
dc.description.sponsorshipAfrican Research Leaders Award
dc.description.sponsorshipResearch Councils UK, RCUK
dc.description.sponsorshipThe Academy of Sciences for the Developing World, TWAS, (Award_17-512 RG/CHE/AF/AC_G)
dc.description.sponsorshipThe Academy of Sciences for the Developing World, TWAS
dc.description.sponsorshipUK Research and Innovation, UKRI, (MR/S00520X/1)
dc.description.sponsorshipUK Research and Innovation, UKRI
dc.identifier.articlenumberM1094
dc.identifier.doi10.3390/m1094
dc.identifier.eissn1422-8599
dc.identifier.issn1422-8599
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85075528182
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/munzur/3559
dc.identifier.volume2019
dc.identifier.wosWOS:000505584600006
dc.language.isoen
dc.publisherMDPI AG
dc.relation.ispartofMolBank
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAlkaloid
dc.subjectAntileishmanials
dc.subjectAntitrypanosomals
dc.subjectImidazole
dc.subjectLeishmaniasis
dc.subjectPaenibacillus
dc.subjectTrypanosomiasis
dc.subject.classificationChemistry, Organic
dc.subject.classificationChemistry
dc.subject.otherIMIDAZOLE DERIVATIVES
dc.titlePaenidigyamycin g: 1-acetyl-2,4-dimethyl-3-phenethyl-1H-imidazol-3-ium
dc.typeArticle
rdl.citation.openalex4
rdl.citation.scopus4
rdl.citation.wos3
rdl.oa.statusgold
rdl.oa.urlhttps://www.mdpi.com/1422-8599/2019/4/M1094/pdf?version=1574354709
rdl.scopus.quartileQ4
rdl.sdgSDG03
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexEmerging Sources Citation Index (ESCI)